What to make of the FDA’s latest CRL drop

By Amanda Conti

The FDA has released its latest batch of Complete Response Letters, continuing an initiative aimed at increasing transparency around regulatory decision-making for drug and biologic applications. The publication follows months of uncertainty over the program and comes as the agency considers additional rulemaking and legislative changes related to CRL disclosure.

The latest release provides new insight into the types of deficiencies cited during product reviews while raising broader questions about how the FDA will balance transparency, confidentiality and sponsor engagement going forward.

This AgencyIQ analysis examines the agency’s evolving approach to CRL disclosure, recent policy developments and what sponsors should be watching next.

Fill out the form to read the full analysis.